MusclePharm Corporation reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was USD 50.04 million compared to USD 64.44 million a year ago. Net loss was USD 12.87 million compared to net income of USD 3.19 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to basic earnings per share from continuing operations of USD 0.1 a year ago. Diluted loss per share from continuing operations was USD 0.39 compared to diluted earnings per share from continuing operations of USD 0.08 a year ago.